Effect of Nasal Calcitonin on the Health-Related Quality of Life in Postmenopause Women Affected With Low Bone Density
- PMID: 26421180
- PMCID: PMC4584075
- DOI: 10.5812/ircmj.17(5)2015.6613
Effect of Nasal Calcitonin on the Health-Related Quality of Life in Postmenopause Women Affected With Low Bone Density
Abstract
Background: Physical activity and mental health could be affected by osteoporosis and various therapeutic options such as calcitonin may influence Quality Of Life (QOL) of these patients with Low Bone Density (LBD).
Objectives: This study aimed to evaluate the effect of nasal calcitonin on QOL in post menopause women with LBD.
Patients and methods: This clinical trial study was performed on one hundred and fifteen menopause women with LBD less than 1 SD in Bone Mineral Densitometry (BMD) referred to Baqiyatallah Hospital in Tehran, Iran, during 2009 - 2010. They were assigned to receive 200 IU calcitonin nasal spray along with calcium (1000 mg) and vitamin D (400 IU) for 6 months. Quality of life was assessed by Short-Form 36 (SF-36) questionnaire (Persian-validated version).
Results: The mean age (± SD) of the participants was 58.75 ± 8.15 years. Intranasal spray of calcitonin increased QOL scores significantly (88.05 ± 15.63 vs. 92.15 ± 13.22, P value = 0.000). Bone mineral density of spine was increased from 0.834 ± 0.11 to 0.12 ± 0.852 and this difference in BMD of lumbar spine was statistically significant (P value: 0.003) but not significant in femur's BMD (P value = 0.061). In comparison with BMD indexes, The QOL scores especially Mental Health domain changes had only a significant correlation with the changes of total T score in BMD (P = 0.031, Coefficient Correlation = 0.248).
Conclusions: It seems that nasal spray of calcitonin can effectively improve QOL of women with LBD and QOL changes were not influenced by clinical or para-clinical alteration. Mental health domain must be more considered in further studies as a predicting domain for Health-Related Quality of Life (HR-QOL) changes.
Keywords: Bone Density; Osteoporosis; Oteoporosis; Postmenopausal; Quality of Life, Calcitonin.
Similar articles
-
Effect of intermittent administration of 200 IU intranasal salmon calcitonin and low doses of 1alpha(OH) vitamin D3 on bone mineral density of the lumbar spine and hip region and biochemical bone markers in women with postmenopausal osteoporosis: a pilot study.Clin Rheumatol. 2005 Jun;24(3):232-8. doi: 10.1007/s10067-004-1004-6. Epub 2005 Jan 13. Clin Rheumatol. 2005. PMID: 15647969 Clinical Trial.
-
A phase 3 trial of the efficacy and safety of oral recombinant calcitonin: the Oral Calcitonin in Postmenopausal Osteoporosis (ORACAL) trial.J Bone Miner Res. 2012 Aug;27(8):1821-9. doi: 10.1002/jbmr.1602. J Bone Miner Res. 2012. PMID: 22437792 Clinical Trial.
-
Nandrolone decanoate and intranasal calcitonin as therapy in established osteoporosis.Osteoporos Int. 1997;7(1):29-35. doi: 10.1007/BF01623456. Osteoporos Int. 1997. PMID: 9102059 Clinical Trial.
-
Calcitonin for the long-term prevention and treatment of postmenopausal osteoporosis.Bone. 2002 May;30(5 Suppl):75S-79S. doi: 10.1016/s8756-3282(02)00715-9. Bone. 2002. PMID: 12008163 Review.
-
Intranasal salcatonin (salmon calcitonin). A review of its pharmacological properties and role in the management of postmenopausal osteoporosis.Drugs Aging. 1996 May;8(5):378-400. doi: 10.2165/00002512-199608050-00006. Drugs Aging. 1996. PMID: 8935399 Review.
References
-
- Genant HK, Cooper C, Poor G, Reid I, Ehrlich G, Kanis J, et al. Interim report and recommendations of the World Health Organization Task-Force for Osteoporosis. Osteoporos Int. 1999;10(4):259–64. - PubMed
-
- Chesnut CH, Silverman S, Andriano K, Genant H, Gimona A, Harris S, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. The American Journal of Medicine. 2000;109(4):267–76. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources